Can avastin stop ovarian cancer from coming back?
NCT ID NCT02884648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that is still present after initial treatment. About 35 women whose cancer was found during a second-look surgery will receive bevacizumab every three weeks. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Avastin)
What this could lead to
If it works, this could offer a way to delay or prevent the return of ovarian cancer after initial treatment.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply widely. Bevacizumab can cause side effects like high blood pressure or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States